Tysabri safety review nearly complete
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Biogen Idec/Elan expect to complete their safety review of Tysabri (natalizumab) by late summer and submit a safety data package to FDA by fall, Biogen Idec says Aug. 9. After Tysabri's marketing withdrawal in February, the sponsors had predicted a re-introduction in the fall. The re-launch is dependent on the final safety review and likely advisory panel consideration, according to Biogen Idec. While the safety review of Tysabri patients with multiple sclerosis is complete, Crohn's and rheumatoid arthritis trial reviews should be complete by late summer, the firm says. Based on a preliminary review of the data, "we would indicate to physicians to not include patients in the clinical trial setting or the commercial setting that have significant immune dysfunction," Biogen Idec CEO Jim Mullen noted during a same-day conference call...
You may also be interested in...
Tysabri resubmission
Biogen Idec and Elan are requesting a priority review for their resubmission of multiple sclerosis therapyTysabri (natalizumab). The sBLA submission, announced Sept. 26, includes a risk management plan with a patient registry, revised labeling, final two-year data from the Phase III AFFIRM monotherapy trial and SENTINEL add-on study with Avonex (interferon beta-1a), as well as an integrated safety assessment of all patients treated with the biologic in clinical trials. The safety data set includes not only the MS pivotal trials but also Crohn's disease and rheumatoid arthritis trials (1Pharmaceutical Approvals Monthly August 2005, In Brief). Biogen Idec previously stated it expects an advisory committee review of the resubmission. Tysabri was withdrawn from the market in February following reports of progressive multifocal leukoencephalopathy from clinical trials...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.